Analyst Ratings for Editas Medicine (EDIT) [Buys]
EDIT Rating Summary
EDIT Price Target Summary
- Highest: $20.00 (Truist Securities)
- Lowest: $8.00 (RBC Capital)
- Average: $14.00
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$14.00 (+150%)
* Over Last 12-Mos
Rating Score: 4.6 / 10
Percentile Rank: 47%
Avg. $ Target:
$14.00 (+150%)
* Over Last 12-Mos
Rating Score: 4.6 / 10
Percentile Rank: 47%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/24/2023 | Citi » Updated 2/28/2024 |
Samantha Semenkow | Upgrade | Buy (Neutral) |
16.00 (11.00) |
6.25 (5.60) |
-10.4% | Details |
| 9/29/2023 | Stifel | Dae Gon Ha | Upgrade | Buy (Hold) |
17.00 (9.00) |
7.11 (5.60) |
-21.24% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
